Medication for influenza
AssigneeTokyo Metropolitan Institute of Medical Science
InventorsFumihiko Yasui, Michinori Kohara
Life of this patent
Estimating the term…
Abstract
A medication for preventing or treating influenza, said medication including an inactivated influenza virus or a recombinant vaccinia virus that includes, within the genome of the vaccinia virus DIs strain, an expression promoter and all or a portion of DNA coding for an influenza virus-derived protein.
Claims20
A method for prophylaxis or treatment of influenza, comprising administering to a subject in need thereof a therapeutically or prophylactically effective amount of a recombinant vaccinia virus that contains an expression promoter and the entire or a part of DNA coding for an influenza virus-derived protein within a genome of a vaccinia virus DIs strain, or an inactivated influenza virus.
A method for prophylaxis or treatment of influenza, comprising administering to a subject in need thereof a therapeutically or prophylactically effective amount of any one of components (a)-(c) below:
- (a) at least one component selected from the group consisting of an activated CD4-positive cell, an activator of a CD4-positive cell and a combination of a CD4-positive cell and an activator of a CD4-positive cell;
- (b) at least one component selected from the group consisting of an activated CD8-positive cell, an activator of a CD8-positive cell and a combination of a CD8-positive cell and an activator of a CD8-positive cell;
- and
- (c) a component consisting of a combination of the components (a) and (b).
A kit for prophylaxis or treatment of influenza, comprising a recombinant vaccinia virus that contains an expression promoter and the entire or a part of DNA coding for an influenza virus-derived protein within a genome of a vaccinia virus DIs strain, or an inactivated influenza virus.
A kit for prophylaxis or treatment of influenza, comprising any one of components (a)-(c) below:
- (a) at least one component selected from the group consisting of an activated CD4-positive cell, an activator of a CD4-positive cell and a combination of a CD4-positive cell and an activator of a CD4-positive cell;
- (b) at least one component selected from the group consisting of an activated CD8-positive cell, an activator of a CD8-positive cell and a combination of a CD8-positive cell and an activator of a CD8-positive cell;
- and
- (c) a component consisting of a combination of the components (a) and (b).
Dependencies are inferred from the claim text.